Objective: The study investigated the possibility of using blood groups as predictive indices for diseases associated with lipid metabolism. Methods: Lipid profiles were examined in 100 apparently healthy male (40) and female (60) subjects of different ABO blood groups aged between 18-30 years from Imo State University. Of these, 20 were blood group A, 30 were B blood type, 4 were AB blood type, and 46 were blood group O. Lipid profile parameters were determined according to enzymatic assay using a commercial kit from Randox Laboratories, United Kingdom and calculation using Friedewald’s equation. Monoclonal ABO blood grouping reagent by CLAS Technology, United Kingdom was used to determine the blood group. Results: Total Cholesterol (140.62 ± 21.66 mg/dl) and High-Density Lipoprotein (HDL) (96.20 ± 40.32 mg/dl) were highest in blood group B. Blood group A had the highest level of Triglyceride (80.84 ± 18.60 mg/dl) and Very Low-Density Lipoprotein (VLDL) (15.21 ± 6.24 mg/dl). Blood group O showed TC level of 130.60 ±34.76 mg/dl with the highest level of LDL (70.74 ± 20.15 mg/dl) and the lowest level of HDL (51.68 ± 20.50 mg/dl) compared to non- O blood types (P < 0.05). Conclusion: The study revealed that blood group O might have a higher propensity for dyslipidemia, suggesting an increased risk for disease associated with lipid metabolism.
Summary:Methaemoglobin, carboxyhaemoglobin concentrations and some haematological parameters were studied in fifty tobacco snuff addicts (40 males and 10 females) in some villages of Anambra State, Nigeria. The aim was to investigate possible adverse effects of tobacco snuff in addicts in Igbos of Anambra State. Fifty apparently healthy persons (25 males and 25 females) who do not inhale snuff were used as controls. The age range of tests and control subjects was 25-65 years. The results showed no statistically significant difference when the tests group was compared with the control group. A comparison of the results on the basis of sex, age and period of exposure, showed no significant differences. Blood picture in test and control groups was normocytic and normochromic. The results suggest that tobacco snuff may not have any adverse effect on haemoglobin metabolism and erythropoiesis.
Metabolic syndrome (MetS) has been variously defined because of varying emphasis placed on its components -dyslipidaemia, hypertension (HBP), hyperglyecmia (HG) and abnormal weight. MetS may be associated with diabetes (DM), HBP, chronic kidney disease (CKD) and apparent health (AH). Unfortunately, the frequency of the diagnostic combination of the risk factors in these conditions has not been reported because it could have therapeutic implications. Data generated in earlier studies on 1107 subjects were analyzed. MetS was diagnosed according to the NCEP-ATP 111 criteria. The frequency of the ten possible diagnostic combinations of the risk factor of MetS was counted and analyzed in each condition associated with the syndrome. The triad, truncal obesity (TO), HBP and decreased high density lipoprotein cholesterol (LHDC) recorded the highest frequency in AH subjects, (males 58.8 and females 38.1%) Among the male patients, HBP, HG and decreased LHDC had the highest frequency (DM, 29.9%; HBP 31.8%; CKD 35.5%). The frequency of the diagnostic triads in the female patients differed from that of the males. The combination of TO, HBP and hypertriglyceridaemia (HTG) absent among the male patients gave the highest frequency in female hypertension and CKD patients. The risk factors combination of TO, HBP and LHDLC can be used for screening MetS in the study population especially among the AH subjects. Moreover, TO appears to be the single most significant risk factor for MetS in the population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.